ISPOR Europe 2024

ISPOR EUROPE 2024 – 17-20 November , Barcelona, Spain

Join EVERSANA and global healthcare leaders as they convene at ISPOR Europe 2024, the leading global conference for Health Economics and Outcomes Research (HEOR).

Our Value & Evidence , Data & Analytics and NAVLIN’s HTA, Pricing & Access experts will be onsite to discuss how we use a variety of analytics, evidence generation, and evidence synthesis activities to help support market access and reimbursement for pharmaceutical and medical devices.

Schedule a meeting with one of our experts to discuss your business needs and visit us in Booth #1413.

---

Don’t Miss Our Featured Spotlight Sessions

• Role of Global Indirect Treatment Comparison (ITC) Programs in Supporting Europe’s Joint Clinical Assessments (JCA): Insights From Global and EU Experts
  Tuesday, 19 November | 13:45 ​​
  MODERATOR: Chris Cameron, MSc, PhD, EVERSANA
  ​PANELISTS: Shannon Cope, MSc, Precision AQ, Vancouver, BC, Canada; Justin Doan, MSc, MPH, DrPH, Global HTA, Value & Evidence, Pfizer, Inc., New York, NY, USA; Uwe Siebert, MD, MPH, MSc, ScD, Institute of Public Health, Medical Decision Making and Health Technology Assessment; Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL – University for Health Sciences and Technology, Austria, Center for Health Decision Science and Dept. of Epidemiology and Health Policy & Management, Harvard T.H. Chan School of Public Health, Institute for Technology Assessment and Department of Radiology; Massachusetts General Hospital; Harvard Medical School, Boston, USA
• ​Bridging Nations, Diverging Views: Exploring the Global Landscape of Indirect Treatment Comparisons Acceptance by Health Technology Assessment Bodies
  Wednesday, 20 November | 10:00 
  MODERATOR: Chris Cameron, MSc, PhD, EVERSANA
  PANELISTS: Stefan Lange, MD, Dierks+Company, Berlin, Germany; Olivia Wu, PhD, Health Economics and Health Technology Assessment (HEHTA) and NIHR Evidence Synthesis Group at the Complex Reviews Synthesis Unit, University of Glasgow, Glasgow, UK; Nicholas Adlard, MA MSc MBA, International HEOR, Novartis Pharmaceuticals UK Ltd, Busserach, SO, Switzerland​

---

EVERSANA’s 2024 Poster Presentations

We are proud to present several posters at this year’s ISPOR Europe conference. Check the links below for more details on each abstract.

SESSION 1: MONDAY, NOVEMBER 18
10:30 –13:30 

• CO9: Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

• EE44: The Economic and Environmental Burden of Hydrophilic and Hydrophobic IOLs in the UK

• HTA54: Review of Cell and Gene Therapies by NICE, HAS, and G-BA: How Did They Fare?

• PCR39: Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L

SESSION 2: MONDAY, NOVEMBER 18 
16:00 –19:00 

• CO65: Indirect Treatment Comparison of Biologic Treatments in Adolescents With Moderate to Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta Analysis

• HTA114: Characterizing Oncology Outcomes in Canada’s Drug Agency (CDA-AMC) Reviews From 2022 -2023

• HTA138: NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs

• PCR75: Patient-Centric Approaches in Rare Disorder Research: An In-Depth Systematic Review

• SA31: Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Treatments for First-Line (1L) Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ) in Adult Patients

SESSION 3: TUESDAY, NOVEMBER 19 
10:30 –13:30 

• EE419: Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems

• EE383: Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Transfusion-Dependent Beta-Thalassemia in Canada

• HPR137: Evaluating the Clinical and Socioeconomic Impact of Improved CKD Diagnosis and Adherence to Guideline-Directed Medical Therapy in Australia, Brazil, and China: An Impact CKD Analysis

• HSD74: Treatment Patterns and Economic Burden of Guillain-Barré Syndrome: A Systematic Review

• HTA173: Evaluating the Impact of Outcome-Based Agreements on Time to Access: Insights From a Comprehensive Database Linkage Study

• HTA221: Market Access Challenges for Gene Therapies in Inherited Blood Disorders: A Retrospective Evaluation of HTA Outcomes for Sickle Cell Disease and Thalassemia

SESSION 4: TUESDAY, NOVEMBER 19 
16:00 –19:00 

• EE532: Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada

• EE553: Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada

• HPR157: CAR-T Cell Therapy Accessibility: A Targeted Review of Access Challenges and Opportunities in APAC Region

• HTA281: Health Economics Studies Assessment of the 2ND China Rare Disease Catalogue: A Scoping Review

• MSR152: A Literature Review to Identify Prognostic Factors and Treatment Effect Modifiers in Population-Adjusted Indirect Comparisons for Multiple Myeloma

• OP12: Role of Health-Economics Application in Enhancing Personalized Medicine: A Comprehensive Systematic Review
• HTA325: Stakeholder Perspectives on the Draft Implementation Act for Joint Clinical Assessments: Key Insights and Concerns

SESSION 5: WEDNSDAY, NOVEMBER 20 
9:00 – 11:30  

• EE791: Cost-Effectiveness Analysis of 1.5% Ruxolitinib Cream for the Treatment of Patients With Atopic Dermatitis in Canada

• EE748: Health Economics Studies Assessment on Melanoma as Part of the 2ND China Rare Disease Catalogue: A Scoping Review

• HPR211: A Targeted Review of Indirect Treatment Comparisons in Global Oncology Drug Regulatory Approval, Reimbursement Recommendations, and Pricing Implications

• PCR312: The Effectiveness of Telemedicine in Improving Access to Healthcare Services: A Systematic Review

• RWD159: Artificial Intelligence in Real-World Evidence Generation: Systematic Review of Applications and Challenges

---

Our Latest Insights on Key Industry Topics

Check out our latest article authored by our team of experts or explore our library of publications to learn more about our RWE/HEOR efforts.